Impact of prior primary tumor resection on long-term prognosis in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: a multicenter analysis
Removing the primary kidney tumor before immunotherapy dramatically improves survival in metastatic kidney cancer, based on long-term real-world follow-up.
In 135 mRCC patients across 8 Japanese institutions with a long 54-month median follow-up, prior primary tumor resection (cytoreductive nephrectomy) was independently associated with markedly better outcomes on nivolumab+ipilimumab, with OS not reached vs. 22 months for non-resected synchronous disease. These long-term real-world data from a Japanese multicenter cohort provide important guidance for patient selection and sequencing of surgery with ICI therapy in mRCC.
What the study was
- Study design
- Retrospective multicenter cohort study; 8 Japanese institutions
- Population
- 135 mRCC patients receiving first-line NIVO+IPI at 8 Japanese institutions; median follow-up 54 months
- Sample size
- 135
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Int J Clin Oncol
Why it surfaced
Long-term (54-month) multicenter Japanese cohort reinforcing role of cytoreductive nephrectomy before NIVO+IPI in mRCC. Retrospective; adds real-world evidence to ongoing CN debate.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.